Verdict: KEEP | Weight: 0.95% (rank 15/50) | Fwd P/E: 14.1 | Next earnings: Apr 23

Factor Decomposition

Trailing 90d regression (n=63 daily):

Model 1: SPY + XBI + QQQ

Model 2: SPY + XLV + QQQ

QQQ beta is statistically zero. In the biotech model (Model 1), QQQ beta = 0.01 with t = 0.02. In the healthcare model (Model 2), QQQ shows 0.94 loading but SPY is -1.01 — multicollinearity artifact. The clean read: GILD moves with XLV (healthcare), not QQQ.

Idio Var 70.8% — slightly below 75% target. Factor variance is from XLV, not tech. Compare to our factor-mismatch removes: MAR beta_MTUM = -0.57, CMCSA -0.56, CSX -0.46, SBUX -0.45, CEG XLU beta = 1.12. Those names actively fight QQQ. GILD is simply indifferent to it.

Financial Summary (8-K FY2025, filed 2026-02-10)

Revenue

P&L

Earnings History (4/4 beats)

Q3's +15.7% beat was the YES2GO reveal quarter. Q1 2026 estimate: $1.91. Street is conservative relative to management's $800M YES2GO guide — $200M/quarter pace starts Q1.

Transcript Analysis (Q4 2025 Call, 2026-02-10)

Management tone: confident but quantified. Headwinds acknowledged precisely ($900M Part D redesign, 2% drug pricing deal, cell therapy -10%). Growth drivers articulated with numbers. Execution-focused language throughout.

Key statements by exec:

Johanna Mercier (EVP Commercial): HIV grew 10% underlying after absorbing $900M Part D headwind. YES2GO "well on way to blockbuster status" — all launch indicators tracking or exceeding. 90% payer coverage, 90% at $0 co-pay. Livdelzi is US market share leader >50% in 2L PBC; competitor product withdrawn. Trodelvy is "only ADC with NCCN guidelines in both 1L and 2L TNBC." Market doubles from 2L to 1L (≈10K women).

Andrew Dickinson (CFO): ≈2% headwind on 2026 from Trump drug pricing deal + ACA changes. "Absent these headwinds, growth would be 6-7%." SG&A increasing mid-single-digit (launch investment), offset by lower G&A. "On average at least 50% of FCF to shareholders."

Daniel O'Day (CEO): "No major LOEs until 2036" — ten-year patent runway. Up to 10 launches through 2027. BD approach: ≈$1B/yr early-stage + disciplined late-stage M&A. "Not the urgency of other companies in the sector" for M&A. This is a CEO not feeling patent pressure — compare to AbbVie/BMY urgency post-Humira/Eliquis.

Dietmar Berger (CMO): Five Phase 3 readouts + five FDA decisions in 2026. Viclen (BIC/LEN daily oral): Phase 3 positive, FDA decision expected year-end. 53 ongoing clinical programs.

Cindy Perettie (EVP Kite): Anito-cel launch H2 2026 in 4L+ myeloma. $3.5B market. 99% manufacturing reliability, 16-day turnaround. Differentiated vs competitors on safety profile.

Phase 3 Failures — Non-Material

ASCENT-07 (Trodelvy 1L HR+/HER2- breast cancer): Missed primary endpoint of PFS by BICR. But this was an expansion into HR+/HER2-, not core franchise. Core TNBC trials (ASCENT-03, ASCENT-04) were both positive, published in NEJM, led to NCCN guideline updates. TNBC franchise intact. Impact: removes one expansion opportunity; core TAM unaffected.

STAR-221 (dom+zim 1L gastric/esophageal cancer): Discontinued on IDMC recommendation. Arcus Biosciences partnership, not core Gilead asset. Also discontinued Phase 2 EDGE-Gastric. Impact: minimal — non-core IO collaboration, never in near-term revenue.

Insider Activity

Clustered C-suite buying: $4.1M net acquired on March 10 — CEO, CFO, CMO, EVP Commercial, and General Counsel all bought on the same day. Partial sales 6 days later ($866K) are consistent with vesting/tax management. CEO's $2.72M net purchase is the largest single buy. Tier 1 signal, LR 2-3 for clustered insider buying.

Market Consensus

Sell-side: unanimously bullish. 23 Buy/Strong Buy, 8 Hold, 0 Sell. Mean target $157 (+16%), median $160. Range $118 (RBC, Sector Perform) to $180 (Jefferies, Buy). Zero bears. 31 analysts — this is a thoroughly covered name.

Recent actions cluster post-Q4 (Feb 10-11): 7 analysts refreshed, all at or above $145. Jefferies raised to $180 on Mar 10 — same day as the C-suite buying cluster.

Estimates: Q1 est $1.91. FY2026 consensus ≈$8.65 (midpoint of guide). Forward P/E 14.1 implies NTM EPS ≈$9.62, which means the street models growth accelerating from +6% (2026) to +15% (NTM/2027). PEG = 14/15 = 0.93 — under 1.0, meaning the market hasn't fully paid up for the acceleration yet. That gap between current P/E and implied growth is where the sell-side +16% upside comes from.

Options market: bullish positioning, elevated vol.

P/C ratio 0.23 on Apr 17 (calls 4.4x puts). Max pain $145, 7% above current. 14,025 call OI at $155 strike — but these are dead positions opened when stock was near $157, now delta ≈0. This is old positioning, not fresh conviction.

Implied earnings move: ≈5.6%. Extracted from term structure (Apr 17 pre-earnings IV vs May 15 post-earnings). For context, Q3 was a +15.7% beat. If YES2GO is tracking above $800M pace, the upside tail is underpriced by options. But this is speculative, not informational edge — we don't have Q1 sales data.

IV at 74th percentile of 52-week range (18%-41%). Elevated but not extreme. Put skew +36% (OTM puts vs ATM) reflects post-selloff fear premium.

Mispricing Assessment

No actionable mispricing identified for filtration purposes.

What looks like mispricing but isn't:

• RSI 21, oversold. Everyone sees this. Options market agrees (P/C 0.23, max pain $145). Mean reversion is a mechanical trade, not an informational edge.
• PEG < 1.0, growth undervalued. 23 buys at mean $157 already prices the acceleration. The 16% upside-to-target IS the market pricing growth re-rating.
• Phase 3 selloff overpriced. Both failures were non-core. Sell-side absorbed this weeks ago, maintained ratings.

What could be mispriced but we can't exploit:

• YES2GO exceeding $800M pace — most specific potential surprise. If Q1 shows $250M+ (vs $150M run-rate), that's a $1B+ annualized pace. But we don't have the data until Apr 23.
• PEPFAR risk — not in consensus, not modeled by any of 31 analysts. If Trump admin cuts international HIV funding, hits lenacapavir PrEP delivery. But we have no edge on White House policy.
• IRA Biktarvy negotiation — $14.3B revenue line enters Medicare price negotiation effective 2028. Real but outside 15-week window.

Edge = P_you - P_market = ≈0%. $168B market cap, 31 analysts, zero information asymmetry.

Filtration Decision

Not Bet 1 (Factor Mismatch)

GILD doesn't fight QQQ — it's indifferent to it (QQQ beta = 0.01). This is categorically different from our anti-momentum removes (MAR, CMCSA, CSX, SBUX) and utility exposure (CEG). Those names actively drag when QQQ rallies. GILD simply doesn't participate.

Adding another zero-IC remove would dilute the research signal. We already have 6 factor bets at zero IC alongside 4 research bets. Gappy says the combined Sharpe is lower than Bet 2 alone. Don't make it worse.

Not Bet 2 (Stock-Specific Weakness)

No management confirmation of underperformance. Opposite: management guides +4-5% base growth with YES2GO as a 5.3x ramp. Insider buying clustered at current levels. No categorical remove trigger (no merger arb, no regulatory event).

Compare to successful removes: MELI (5 consecutive quarters refusing margin optimization, confirmed by management), SBUX (turnaround is September, window is July), VRTX (flat EPS + insider selling). GILD has accelerating revenue, insider buying, and positive catalyst skew.

Regime Dependence

At zero QQQ beta, GILD's filtration contribution depends entirely on regime:

• QQQ rallies hard: GILD is 95bp of dead weight (doesn't participate)
• QQQ sells off or chops: GILD's defensiveness helps the long basket

Over the past 81 days: GILD +9.2%, QQQ -8.8%. In the current risk-off tape, GILD is carrying weight. Whether this regime persists is a macro call — not detective work, and not our edge.

Weight Impact

At 0.95%, even 10% relative underperformance = 9.5 bps to the basket. De minimis.

Verdict: KEEP

No factor mismatch to exploit, no stock-specific weakness confirmed by management, zero informational edge at $168B market cap with 31 analysts, clustered insider buying, 4/4 earnings beats, positively skewed catalyst calendar, and 0.95% weight makes the position immaterial regardless. Burden of proof on removal is not met. The evidence actively argues against removal (LR 0.5).

In-Window Catalysts

What Would Change This

• Q1 earnings miss + YES2GO tracking below $500M pace (Apr 23) — re-evaluate
• PEPFAR funding cut announced — check lenacapavir PrEP delivery impact
• QQQ enters sustained rally (+15%) while GILD flat — regime shift makes defensive weight a drag, but this is a macro call, not a GILD-specific remove

Worldview Factors (6 active, 0 scenarios)

None change the filtration decision. Most are long-dated DEMAND factors with low loading.

Sources